Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Bai

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|March 27, 2017
Weighted win loss approach for analyzing prioritized outcomesXiaodong Luo, Junshan Qiu, Steven Bai, et al.
Statistics in Medicine|October 4, 2018
Design and monitoring of survival trials in complex scenariosXiaodong Luo, Xuezhou Mao, Xun Chen, et al.
Journal of Biopharmaceutical Statistics|September 7, 2020
Estimation on conditional restricted mean survival time with counting processJunshan Qiu, Dali Zhou, H M Jim Hung, et al.
Journal of Biopharmaceutical Statistics|August 28, 2019
Estimation on conditional restricted mean survival time with counting processJunshan Qiu, Ennan Gu, Dali Zhou, et al.
Contemporary Clinical Trials|December 5, 2022
Statistical power considerations in the use of win ratio in cardiovascular outcome trialsBang Wang, Dali Zhou, Jialu Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitorsJeffrey G Varnes, Dean A Wacker, Donald J P Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitorsJeffrey G Varnes, Dean A Wacker, Irina C Jacobson, et al.
Journal of Medicinal Chemistry|April 14, 2009
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Todd Clarke, Liqi He, et al.
Journal of Medicinal Chemistry|December 4, 2003
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1)James R Pruitt, Donald J P Pinto, Robert A Galemmo, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|March 27, 2017
Weighted win loss approach for analyzing prioritized outcomesXiaodong Luo, Junshan Qiu, Steven Bai, et al.
Statistics in Medicine|October 4, 2018
Design and monitoring of survival trials in complex scenariosXiaodong Luo, Xuezhou Mao, Xun Chen, et al.
Journal of Biopharmaceutical Statistics|September 7, 2020
Estimation on conditional restricted mean survival time with counting processJunshan Qiu, Dali Zhou, H M Jim Hung, et al.
Journal of Biopharmaceutical Statistics|August 28, 2019
Estimation on conditional restricted mean survival time with counting processJunshan Qiu, Ennan Gu, Dali Zhou, et al.
Contemporary Clinical Trials|December 5, 2022
Statistical power considerations in the use of win ratio in cardiovascular outcome trialsBang Wang, Dali Zhou, Jialu Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitorsJeffrey G Varnes, Dean A Wacker, Donald J P Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitorsJeffrey G Varnes, Dean A Wacker, Irina C Jacobson, et al.
Journal of Medicinal Chemistry|April 14, 2009
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Todd Clarke, Liqi He, et al.
Journal of Medicinal Chemistry|December 4, 2003
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1)James R Pruitt, Donald J P Pinto, Robert A Galemmo, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
Pageof 1